Eurand and GSK Reach Development Milestone

by Medindia Content Team on  June 7, 2007 at 2:28 PM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

Eurand and GSK Reach Development Milestone
Eurand N.V., a global specialty pharmaceutical company, announced today that Eurand, Inc. and its collaboration partner, GlaxoSmithKline (NYSE: GSK), reached a significant milestone in the development of an orally disintegrating tablet formulation of an undisclosed compound.

GSK has started a registration bioequivalence study for the new formulation and will make a milestone payment of $1 million to Eurand in recognition of the initiation of this biostudy.

"We are delighted with how well this new formulation is progressing for GlaxoSmithKline," said Gearoid Faherty, Chief Executive Officer, Eurand. "Using our Microcaps(R) and AdvaTab(R) technologies, we develop fast dissolving dosage forms that make it easier for patients to take their medicine.

The new formulation for GlaxoSmithKline dissolves in the mouth in approximately 30 seconds without water and without leaving a bitter or sour taste."

GSK intends to file for marketing authorization in the United States by the end of 2007.

Source: PRNewswire
LIN/M

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive